Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk reports lower-than-expected Q3 results, missing both earnings and revenue estimates. Management updates 2024 financial guidance.

NVO Misses Q3 Earnings & Revenue Estimates, Updates 2024 View

Novo Nordisk A/S (NVO) Q3 2024 Earnings Conference Call November 6, 2024 7:00 AM ET Company Participants Jacob Martin Wiborg Rode - Head of Investor Relations Lars Fruergaard Jorgensen - President and Chief Executive Officer Camilla Sylvest - Executive Vice President and Head of Commercial Strategy & Corporate Affairs Doug Langa - Executive Vice President and Head of North America Operations Martin Holst Lange - Executive Vice President and Head of Development Karsten Munk Knudsen - Executive Vice President and Chief Financial Officer Conference Call Participants Richard Parkes - BNP Paribas Exane Sachin Jain - Bank of America Louise Chen - Cantor Fitzgerald Michael Nedelcovych - TD Cowen Jo Walton - UBS Richard Vosser - JPMorgan Florent Cespedes - Bernstein Martin Parkhoi - SEB Kerry Holford - Berenberg Mattias Haggblom - Handelsbanken Operator Good day, and thank you for standing by. Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call.

Novo Nordisk A/S (NVO) Q3 2024 Earnings Call Transcript

After rising in premarket trading, Novo Nordisk's (NVO) U.S.-listed shares fell after the market opened Wednesday as its third-quarter sales fell short of estimates despite continued growth form weight-loss drugs Ozempic and Wegovy.

Novo Nordisk Stock Slips as Sales Grow Less Than Expected

Novo Nordisk stock inched down Wednesday after the drugmaker's weight-loss drug beat forecasts, but sales of its diabetes behemoth missed. The post Novo Nordisk Dips After Tightening Its Outlook As Wegovy Beats, But Ozempic Misses appeared first on Investor's Business Daily.

Novo Nordisk Dips After Tightening Its Outlook As Wegovy Beats, But Ozempic Misses

Novo Nordisk's sales growth next year could be in the high teens in percentage terms, Chief Financial Officer Karsten Munk Knudsen said on an analyst call following the release of third-quarter earnings on Wednesday.

Novo Nordisk CFO says 2025 sales could see high-teens percentage growth

Novo Nordisk's (NVO) U.S.-listed shares rose Wednesday morning as it reported better third-quarter profits than expected, though sales of its drugs including popular weight-loss treatments Ozempic and Wegovy grew less than expected.

Novo Nordisk Stock Rises on Earnings Beat, Narrowed Outlook

Novo Nordisk reported forecast-beating quarterly sales of its popular Wegovy weight-loss drug on Wednesday, sending its shares up nearly 9%.

Novo Nordisk CEO on Wegovy prices, supplies and compounding

Novo Nordisk on Wednesday nudged higher its outlook for the year as the drugmaker registered another quarter of strong sales of its weight-loss drugs.

Ozempic maker Novo Nordisk nudges higher profit forecast

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new injection will deliver 25% weight loss.

Novo Nordisk says its experimental drug CagriSema has similar side effects to Wegovy

Novo Nordisk is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and is increasing supply in that market, its CEO said on Wednesday.

Novo Nordisk lifts curbs on Wegovy prescriptions in the U.S., says CEO

Novo Nordisk is aware of 100 hospitalizations and 10 deaths resulting from people taking compounded copies of its popular weight-loss and diabetes drugs, the drugmaker's finance chief said on Wednesday.

Novo Nordisk says it is aware of 10 deaths from compounded weight-loss drug copies

Novo Nordisk (NYSE:NVO) reported better-than-expected third-quarter sales of its weight-loss drug Wegovy, reaching $2.49 billion, exceeding analyst expectations of $2.29 billion and increasing 48% from the previous quarter. The strong performance is seen as a positive sign amid competition from Eli Lilly's obesity drug, Zepbound.

Novo Nordisk Q3 numbers boosted by Wegovy beat

The pharmaceutical giant narrowed its full-year guidance after its blockbuster Wegovy weight-loss drug beat sales expectations in the third quarter.

Novo Nordisk's Wegovy Sales Beat Expectations

Novo Nordisk quarterly profit meets expectations as Wegovy maker narrows full-year guidance

Bagsværd, 6 November 2024  - Financial report for the period 1 January 2024 to 30 September 2024

Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.7 billion in the first nine months of 2024

Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted third-quarter operating profit in line with expectations and narrowed its full-year sales and profit guidance range.

Novo Nordisk Q3 in line with expectations, narrows FY guidance range

Investors want assurance the new GLP-1 weight-loss medicines can live up to their blockbuster expectations.

Novo Nordisk Earnings Are Soon. It's All About Weight-Loss Drug Sales.

Gilead Sciences

Moderna

Teva Pharmaceutical

Viatris

Let us look at five large biotech and generic drug companies, NVO, GILD, MRNA, VTRS and TEVA, which are gearing up for their earnings releases this week.

What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?

Pfizer

Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Pfizer (PFE) or Novo Nordisk (NVO). But which of these two stocks presents investors with the better value opportunity right now?

PFE or NVO: Which Is the Better Value Stock Right Now?

Novo Nordisk AS NVO will report third-quarter earnings on Wednesday. Wall Street expects 88 cents in EPS and $10.49 billion in revenues when the company reports after market hours.

Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?

Hims & Hers Health

The telehealth company will launch a generic version of Novo's type 2 diabetes drug liraglutide in 2025.

Hims & Hers Stock Jumps. A Generic Version of Novo Nordisk Diabetes Drug Is Close.

Catalent

Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.

Catalent misses Q1 revenue estimates ahead of $16.5 bln deal close with Novo Holdings

Eli Lilly

Americans are still eagerly seeking prescriptions for Eli Lilly and Novo Nordisk's weight-loss and diabetes drugs but cannot always fill them because of supply issues and insurance hurdles, according to their doctors.

Americans seeking Eli Lilly and Novo Nordisk's weight-loss drugs turn to compounded market

Ambev

Automatic Data Processing

ASML Hld

ConocoPhillips

Cintas Corp

Dick's Sporting Goods

Devon Energy

EOG Resources

Diamondback Energy

Hershey

Infosys

Lam Research

Monolithic Power Systems

MSCI

Old Dominion Freight Line

Paychex

Rollins

Schwab US Dividend Equity ETF

Visa

Watsco

The 4-factor dividend growth portfolio is a strategy that leverages the stock selection process of Schwab U.S. Dividend Equity ETF with a few minor twists. The portfolio finished FY2 on October 31, 2024, with a total return of 33.27%. Since its inception, the portfolio has generated a CAGR of 21.57%, and is outperforming SCHD by 10.30%.

4-Factor Dividend Growth Portfolio: FY3 Rebalance And 21.57% Long-Term CAGR

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.

Hims & Hers Health plans to offer generic version of Novo Nordisk's diabetes drug in 2025

News for Novo Nordisk Stock (NVO)